{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nafcillin", "query": { "intervention": "nafcillin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nafcillin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T20:13:45.084Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00077675", "title": "Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infections, Gram-positive Bacterial" ], "interventions": [ { "name": "Telavancin", "type": "DRUG" }, { "name": "vancomycin or antistaphylococcal penicillin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cumberland Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 201, "start_date": "2004-02", "completion_date": "2004-09", "has_results": true, "last_update_posted_date": "2019-01-16", "last_synced_at": "2026-09-05T20:13:45.084Z", "location_count": 1, "location_summary": "National City, California", "locations": [ { "city": "National City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077675" }, { "nct_id": "NCT01431326", "title": "Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenovirus", "Anesthesia", "Anxiety", "Anxiolysis", "Autism", "Autistic Disorder", "Bacterial Meningitis", "Bacterial Septicemia", "Benzodiazepine", "Bipolar Disorder", "Bone and Joint Infections", "Central Nervous System Infections", "Convulsions", "Cytomegalovirus Retinitis", "Early-onset Schizophrenia Spectrum Disorders", "Epilepsy", "General Anesthesia", "Gynecologic Infections", "Herpes Simplex Virus", "Infantile Hemangioma", "Infection", "Inflammation", "Inflammatory Conditions", "Intra-abdominal Infections", "Lower Respiratory Tract Infections", "Migraines", "Pain", "Pneumonia", "Schizophrenia", "Sedation", "Seizures", "Skeletal Muscle Spasms", "Skin and Skin-structure Infections", "Treatment-resistant Schizophrenia", "Urinary Tract Infections", "Withdrawal", "Sepsis", "Gram-negative Infection", "Bradycardia", "Cardiac Arrest", "Cardiac Arrhythmia", "Staphylococcal Infections", "Nosocomial Pneumonia", "Neuromuscular Blockade", "Methicillin Resistant Staphylococcus Aureus", "Endocarditis", "Neutropenia", "Headache", "Fibrinolytic Bleeding", "Pulmonary Arterial Hypertension", "CMV Retinitis", "Hypertension", "Chronic Kidney Diseases", "Hyperaldosteronism", "Hypokalemia", "Heart Failure", "Hemophilia", "Heavy Menstrual Bleeding", "Insomnia" ], "interventions": [ { "name": "The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daniel Benjamin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 3520, "start_date": "2011-11", "completion_date": "2019-11", "has_results": false, "last_update_posted_date": "2023-09-06", "last_synced_at": "2026-09-05T20:13:45.084Z", "location_count": 43, "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01431326" }, { "nct_id": "NCT05001750", "title": "Prophylactic Antibiotics Useful With Antibiotic Impregnated External Ventricular Drains (EVDs)?", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Subarachnoid Hemorrhage", "Intracerebral Hemorrhage", "Ventriculitis, Cerebral", "Hydrocephalus" ], "interventions": [ { "name": "Long term (continuous) prophylactic antibiotics", "type": "DRUG" }, { "name": "24 hours antibiotics", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2021-06-14", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-09-05T20:13:45.084Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05001750" }, { "nct_id": "NCT00061633", "title": "Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infections, Gram-Positive Bacterial", "Abscess", "Burns", "Cellulitis", "Ulcer", "Wound Infections" ], "interventions": [ { "name": "Telavancin", "type": "DRUG" }, { "name": "Vancomycin or antistaphylococcal penicillin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cumberland Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2003-06", "completion_date": "2004-01", "has_results": true, "last_update_posted_date": "2019-01-16", "last_synced_at": "2026-09-05T20:13:45.084Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00061633" }, { "nct_id": "NCT07376889", "title": "Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Staphylococcus Aureus Bacteremia" ], "interventions": [ { "name": "Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)", "type": "DRUG" }, { "name": "Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)", "type": "DRUG" }, { "name": "Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)", "type": "DRUG" }, { "name": "Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intermountain Health Care, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2096, "start_date": "2026-02-01", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-05T20:13:45.084Z", "location_count": 13, "location_summary": "Brighton, Colorado • Denver, Colorado • Grand Junction, Colorado + 10 more", "locations": [ { "city": "Brighton", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Grand Junction", "state": "Colorado" }, { "city": "Lafayette", "state": "Colorado" }, { "city": "Wheat Ridge", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07376889" }, { "nct_id": "NCT02099240", "title": "Patients Response to Early Switch To Oral:Osteomyelitis Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Osteomyelitis" ], "interventions": [ { "name": "oral antibiotics", "type": "DRUG" }, { "name": "intravenous antibiotics", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Julio Ramirez", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 11, "start_date": "2014-03-06", "completion_date": "2018-11-07", "has_results": false, "last_update_posted_date": "2021-04-06", "last_synced_at": "2026-09-05T20:13:45.084Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02099240" }, { "nct_id": "NCT00711802", "title": "Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Skin Diseases, Infectious" ], "interventions": [ { "name": "Daptomycin", "type": "DRUG" }, { "name": "Standard of Care (SOC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 396, "start_date": "2008-07-23", "completion_date": "2013-10-11", "has_results": true, "last_update_posted_date": "2018-09-05", "last_synced_at": "2026-09-05T20:13:45.084Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Oakland, California • Orange, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00711802" }, { "nct_id": "NCT00428844", "title": "Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteomyelitis" ], "interventions": [ { "name": "daptomycin", "type": "DRUG" }, { "name": "vancomycin", "type": "DRUG" }, { "name": "teicoplanin", "type": "DRUG" }, { "name": "nafcillin", "type": "DRUG" }, { "name": "oxacillin", "type": "DRUG" }, { "name": "flucloxacillin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 75, "start_date": "2007-06-26", "completion_date": "2010-06-23", "has_results": true, "last_update_posted_date": "2018-01-31", "last_synced_at": "2026-09-05T20:13:45.084Z", "location_count": 17, "location_summary": "Little Rock, Arkansas • Englewood, Colorado • Washington D.C., District of Columbia + 14 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Idaho Falls", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT00428844" }, { "nct_id": "NCT01191840", "title": "Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bacteremia" ], "interventions": [ { "name": "Vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 509, "start_date": "2011-02", "completion_date": "2017-03-04", "has_results": true, "last_update_posted_date": "2018-01-05", "last_synced_at": "2026-09-05T20:13:45.084Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01191840" }, { "nct_id": "NCT04775953", "title": "DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Staphylococcal Bacteraemia" ], "interventions": [ { "name": "Cefazolin", "type": "DRUG" }, { "name": "Dalbavancin", "type": "DRUG" }, { "name": "Daptomycin", "type": "DRUG" }, { "name": "Nafcillin", "type": "DRUG" }, { "name": "Oxacillin", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 200, "start_date": "2021-04-22", "completion_date": "2023-12-01", "has_results": true, "last_update_posted_date": "2024-12-10", "last_synced_at": "2026-09-05T20:13:45.084Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Sacramento, California • Torrance, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04775953" } ] }